greeksoup/ stock research
Stock research / Foreign companies / RDY · Pharmaceutical Preparations

Dr. Reddy’s Laboratories Limited (RDY)

Dr. Reddy's Laboratories makes generic medicines, the active ingredients that go into them, and a growing set of biosimilars. It was incorporated in India under the Companies Act, 1956 as a private limited company on 24 February 1984 by its promoter and former chairman, the late Dr. K. Anji Reddy, with the stated objective of developing and supplying pharmaceutical products at affordable prices. The registered office is in Banjara Hills, Hyderabad. The equity shares have been listed on the BSE and the National Stock Exchange of India since 6 December 1985, and the American depositary shares on the New York Stock Exchange since 11 April 2001, with a secondary listing on NSE International Exchange in GIFT City since 9 December 2020. The financial year ends in March and figures are stated in rupees.

Dr. Reddy’s Laboratories Limited

Dr. Reddy's Laboratories makes generic medicines, the active ingredients that go into them, and a growing set of biosimilars. It was incorporated in India under the Companies Act, 1956 as a private limited company on 24 February 1984 by its promoter and former chairman, the late Dr. K. Anji Reddy, with the stated objective of developing and supplying pharmaceutical products at affordable prices. The registered office is in Banjara Hills, Hyderabad. The equity shares have been listed on the BSE and the National Stock Exchange of India since 6 December 1985, and the American depositary shares on the New York Stock Exchange since 11 April 2001, with a secondary listing on NSE International Exchange in GIFT City since 9 December 2020. The financial year ends in March and figures are stated in rupees.

Three segments

Global Generics manufactures and markets prescription and over-the-counter finished products ready for the patient, either under a brand name or as generic finished dosages therapeutically equivalent to a branded formulation. It also holds the biologics business and the portfolio outside the United States of consumer nicotine replacement therapy brands acquired from Haleon UK Enterprises Limited. Pharmaceutical Services and Active Ingredients makes and markets active pharmaceutical ingredients and intermediates, the principal inputs to a finished medicine, plus semi-finished and finished formulations, and runs a pharmaceutical services business providing contract research and making ingredients to a customer's specification. Others holds Aurigene Oncology Limited and the Proprietary Products business.

Where it sells

The key markets named are the United States, India, Russia and other countries of the former Soviet Union, and Europe. Global generics has remained the largest contributor, with the company reporting increased focus on complex products, injectables and specialty molecules, particularly in regulated markets such as the United States and Europe. Alongside branded and unbranded generics sit consumer healthcare products and a small set of new medicines of the company's own. The filing states that the company focuses on unserved, underserved or unarticulated patient needs through new chemical entities, new biological entities and cell and gene therapies.

Biosimilars

Biosimilars have been expanded mainly through development and commercialisation partnerships, which the company says lets it enter complex and higher-value categories while managing development risk and capital intensity. A 2024 partnership with Alvotech covers commercialisation of a biosimilar candidate to Prolia and Xgeva, denosumab, in the United States and Europe. A 2025 partnership with Shanghai Henlius Biotech covers the daratumumab biosimilar HLX15 in the same two markets. Following launches in India and other emerging markets, the business has moved into highly regulated markets.

The US pipeline

Fifteen new Abbreviated New Drug Applications were filed with the U.S. FDA in the year to March 2026. At the end of that year 77 generic filings were pending FDA approval: 75 ANDAs and 2 New Drug Applications filed under Section 505(b)(2). Of the 75 ANDAs, 43 are Paragraph IV applications, and the company states that it believes 22 of those carry First to File status. Approval timelines are shaped by patent challenges and statutory exclusivity periods, including pediatric exclusivity, orphan drug exclusivity and the 180-day exclusivity available to a first Paragraph IV filer.

Plants and spending

Contractual capital commitments stood at Rs 9,716 million at the end of March 2026, primarily relating to capacity, and the company states that it expects to fund those and its planned capital spending from internal operating cash flows and existing investments. Capital spending goes primarily on manufacturing facilities, research and development facilities and other fixed assets. The UK facilities are licensed and periodically inspected by the MHRA good manufacturing practice Inspectorate, which has also approved and inspects the manufacturing facilities at Hyderabad and Vishakhapatnam in India for medicines supplied to the United Kingdom. In the United States, generic drugs marketed under an ANDA carry a required Medicaid rebate of 13% of the average manufacturer price.

From Dr. Reddy's annual report on Form 20-F for the year ended 31 March 2026. The filing

Compare with another name

Dr. Reddy’s Laboratories Limited files a 20-F with the SEC once a year, in Indian rupees. In the year to 31 March 2026 it reported revenue of INR 335,933 million ($3.8 billion at the year's average rate), up 3.2% on the year before. Its profit attributable to shareholders was INR 42,850 million, down 24.2%, and diluted earnings per share INR 51.42.

Dr. Reddy’s Laboratories (RDY) in brief

Dr. Reddy’s Laboratories (RDY) reported revenue of INR 336 billion for the year to 31 March 2026, up 3.2% on the year before.
Read moreProfit attributable to shareholders was INR 42.9 billion and diluted earnings per share INR 51.42. Revenue was INR 326 billion in the year to 31 March 2025, INR 279 billion in the year to 31 March 2024, INR 246 billion in the year to 31 March 2023 and INR 214 billion in the year to 31 March 2022. Profit attributable to shareholders in the same years was INR 56.5 billion, INR 55.7 billion, INR 45.1 billion and INR 23.6 billion. Revenue grew 12.1% a year, compounded, over the five years to the year to 31 March 2026. At the close of 10 November 2026 the market cap of Dr. Reddy’s Laboratories was $12.4 billion, 27.1 times its earnings for the year to 31 March 2026.

The share in the US

Last close$14.87 on 10 November 2026
52-week range$11.38 (22 July 2026) to $15.38 (26 June 2026)
Over one yearup 9.9%
Market cap$12.4 billion: 834,656,970 shares outstanding at 31 March 2026 (20-F), each US share standing for one ordinary share
P/E, latest fiscal year27.1: the last close over diluted EPS for the year to Mar 2026, INR 51.42 per ordinary share, $0.55 at 93.91 INR per US dollar on 6 November 2026 (FRED DEXINUS). The company reports once a year, so this is the latest fiscal year, not the last four quarters.

US dollars per share as it trades in the US; the market cap and the P/E are worked out here, not filed. Prices from IEX, for splits.

Ratios

From the latest annual report, the year to Mar 2026, in dollars

ROE11.4%
ROCE11.1%
Operating margin15.0%
Net margin12.8%
FCF margin10.0%
Interest cover13.52
Debt to equity0.21
Cash conversion1.32
Share count, last 12 months-0.1%
Sales CAGR, 3 years11.0%
Profit CAGR, 3 years-1.7%
EPS$0.55

At the close of 10 November 2026

Price$14.87
Market cap$12.4 billion
Stock P/E27.15
Price to book3.09
EV / EBITDAn/a
Dividend yield0.6%
Market cap / sales3.47
52-week high$15.38
52-week low$11.38
Price, 1 year9.9%
Price CAGR, 3 yearsn/a
Price CAGR, 5 yearsn/a
Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Dr. Reddy’s Laboratories Limited's balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.
RDYgreeksoup.ai
Daily prices to 10 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. This company reports once a year, so every view here moves once a year, on the day each annual report was filed, and holds until the next. P/E is the close over the year's EPS per US share: the EPS as filed, in dollars at the year's average exchange rate (Federal Reserve, from FRED). Sales and margin are each year's revenue in dollars and its operating margin. EV/EBITDA, price to book and market cap to sales set the close against that year's balance sheet in dollars at its year-end rate and its share count per US share. Years before a share split are put on today's shares. The dashed line is the median over the range shown. The P/E above uses today's exchange rate, so the latest point here can differ from it a little. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on RDY

DividendsINR 40.00 a share in FY2025
Filings123 in twelve months: 122 reports on Form 6-K, most often intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings (13); disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (13); allotment of Equity Shares on exercise of Stock Options under ESOPs (10); intimation regarding Board meeting and trading window closure (4); review Report of Independent Registered Public Accounting Firm (3)
Planned insider sales1 Form 144 notice in twelve months, $6.5 million; latest 2 November 2026
Options tapeput/call 0.01 by open interest at the 10 November 2026 close; the straddle prices a 33.3% move to 20 November 2026
13F holders239 funds reported a position for the quarter to 30 June 2026; largest Robeco Institutional Asset Management B.V.
Congress0 House trades disclosed in six months
Short interest25.3 million shares short, 7.81 days to cover at 30 October 2026

Income statement (profit and loss), 11 fiscal years

Year toMar 2016Mar 2017Mar 2018 †Mar 2019 †Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue154,708140,809142,028153,851174,600189,722214,391245,879279,164325,535335,933
Cost of sales62,42762,45365,72470,42180,59186,645100,551106,536115,557135,107158,669
Gross profit92,28178,35676,30483,43094,009103,077113,840139,343163,607190,428177,264
Research and development17,83419,55118,26515,60715,41016,54117,48219,38122,87327,38024,058
Selling, general and administrative45,70246,37246,85748,68050,12954,65062,08168,02677,20193,870106,763
Operating profit29,61913,49811,91720,88815,99324,28029,47657,14467,72971,84350,551
Finance costs4,9597818171,1639839709581,4281,7112,8293,738
Profit before tax27,14014,65314,34122,44318,03226,41332,29860,36771,87076,78454,817
Income tax7,1272,6144,5353,648-1,4669,1758,73015,30016,18619,53912,351
Profit for the year20,01312,0399,80618,79519,49817,23823,56845,06755,68457,24542,466
Profit attributable to shareholders20,01312,0399,80618,79519,49817,23823,56845,06755,68456,54442,850
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F
INR million, from each year's annual report on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated. A year marked † shows the figure as the company restated it in a later annual report (Mar 2018, Mar 2019); the first-filed figure is in the CSV. For Mar 2019, Mar 2020, Mar 2021, Mar 2022 the company files only its profit available to ordinary shareholders, after amounts due to holders of preference shares, and that is the figure shown; the other years are the profit attributable to the parent's shareholders. Profit for the year includes the part that belongs to minority shareholders; profit attributable to shareholders is the part EPS is struck on. Each year links to its own page.
Year toMar 2016Mar 2017Mar 2018 †Mar 2019 †Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Diluted EPS116.9872.0959.00113.09117.40103.65141.6954.1766.8067.7851.42
Basic EPS117.3472.2459.13113.28117.63103.94142.0854.2866.9367.8851.48
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

INR per ordinary share, as filed. One US-listed share can stand for more or fewer ordinary shares; the P/E above puts the two on the same basis.

Revenue by region

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Share
of the parts, latest year
Others34,51936,08540,44949,58360,95268,96267,46972,82594,396118,71835.3%
United Statesn/an/an/an/an/a80,564106,683135,565149,351117,89235.1%
India24,92725,20928,80432,08936,25243,98650,49948,47355,83064,53719.2%
Russia11,54712,61015,29916,90015,81620,87921,22822,30125,95834,78610.4%
Oncology69,81668,12469,29976,02876,702n/an/an/an/an/an/a
OthersUnited States FY2022 to FY2026IndiaRussiaOncology FY2017 to FY2021
142.0Mar 2018174.6Mar 2020214.4Mar 2022279.2Mar 2024335.9Mar 2026

INR billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

INR million, from the latest 20-F, in the company's own words. A year is shown only where the parts add up to the revenue above.

Cash flow statement

Year toMar 2016Mar 2017Mar 2018 †Mar 2019 †Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operations41,24721,51318,02928,70429,84135,70328,10858,87545,43346,42856,755
Purchase of property, plant and equipment12,01712,2789,2916,9554,8469,74114,66011,32316,40327,50423,326
Free cash flow29,2309,2358,73821,74924,99525,96213,44847,55229,03018,92433,429
Cash from investing-20,423-18,471-14,883-7,727-4,923-22,660-26,387-41,373-40,283-58,077-65,513
Cash from financing-17,001-3,692-4,440-21,326-25,159-298-2,422-26,861-3,76318,9118,290
Depreciation and amortisation10,25011,27711,71012,19012,47212,79611,82412,63614,84117,05820,605
Buybacks0.015,6940.00.04741,1930.0n/an/an/an/a
Dividends paid4,1063,3903,9924,0023,9164,1474,1464,9796,6486,6626,659
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F
INR million, from the cash flow statement as filed.
Read morePurchase of property, plant and equipment is the cash line as filed; purchases of intangible assets and acquisitions are not in it. Free cash flow is cash from operations less that purchase, arithmetic on the two filed lines. Cash from investing and from financing are the company's own section totals, below zero where cash went out. Buybacks are the cash paid for the company's own shares.

Balance sheet at year end

Year toMar 2016Mar 2017Mar 2018 †Mar 2019 †Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Funded by
Equity attributable to shareholders128,336124,044126,460140,197154,988173,062190,527230,991280,550333,388377,063
Non-controlling interestsn/an/an/an/an/an/an/an/a0.03,7783,394
Borrowings, as filedn/a49,09850,61838,38122,01130,29933,84513,47220,02046,76677,341
Lease liabilitiesn/an/an/a6091,7873,363n/an/an/an/a5,436
Other liabilitiesn/a46,67948,52646,24053,45558,76768,45577,39186,948109,057116,112
Total equity and liabilitiesn/a219,821225,604225,427232,241265,491292,827321,854387,518492,989579,346
Owned
Property, plant and equipmentn/a57,16057,86954,08852,33257,11162,16966,46276,88697,761115,930
Goodwilln/a3,7523,9453,9023,9944,5684,4184,2454,25311,81012,893
Other intangible assets20,79644,92544,66544,36727,65935,64827,24630,84936,95196,803105,059
Cash and cash equivalentsn/a3,8662,6382,2282,05314,82914,8525,7797,10714,65415,368
Trade and other receivablesn/a38,06540,61739,86950,27849,64166,76472,48580,29890,420101,219
Inventoriesn/a28,52929,08933,57935,06645,41250,88448,67063,55271,08576,531
Other assetsn/a43,52446,78147,39460,85958,28266,49493,364118,471110,456152,346
Total assetsn/a219,821225,604225,427232,241265,491292,827321,854387,518492,989579,346
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F
INR million, at each fiscal year end.
Read moreBoth totals are the company's own; other liabilities and other assets are each total less the rows shown. Borrowings is the company's own stated total where it files one; it is never added up from its parts here.

Ratios on the filed lines

Year toMar 2016Mar 2017Mar 2018 †Mar 2019 †Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross margin59.6%55.6%53.7%54.2%53.8%54.3%53.1%56.7%58.6%58.5%52.8%
Operating margin19.1%9.6%8.4%13.6%9.2%12.8%13.7%23.2%24.3%22.1%15.0%
Net margin12.9%8.5%6.9%12.2%11.2%9.1%11.0%18.3%19.9%17.4%12.8%
Free cash flow margin18.9%6.6%6.2%14.1%14.3%13.7%6.3%19.3%10.4%5.8%10.0%
Return on year-end equity15.6%9.7%7.8%13.4%12.6%10.0%12.4%19.5%19.8%17.0%11.4%
Effective tax rate26.3%17.8%31.6%16.3%-8.1%34.7%27.0%25.3%22.5%25.4%22.5%
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

Arithmetic on the filed lines of the same year: margins over revenue, return on equity as profit attributable to shareholders over year-end equity, tax over profit before tax.

Questions

What was Dr. Reddy’s Laboratories' revenue in the year to 31 March 2026?

Dr. Reddy’s Laboratories (RDY) reported revenue of INR 336 billion for the year to 31 March 2026, up 3.2% on the year before.

How much did Dr. Reddy’s Laboratories earn in the year to 31 March 2026?

Profit attributable to shareholders was INR 42.9 billion for the year to 31 March 2026, and diluted earnings per share INR 51.42.

What is Dr. Reddy’s Laboratories' P/E ratio?

At the close of 10 November 2026, Dr. Reddy’s Laboratories traded at 27.1 times its earnings for the year to 31 March 2026.

What is Dr. Reddy’s Laboratories' market cap?

The market cap of Dr. Reddy’s Laboratories was $12.4 billion at the close of 10 November 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.35 trillion46.5168.5%n/a45.5%1.230.4%
Johnson & Johnson JNJ$675.9 billion42.5419.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$519.4 billion50.58n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$364.8 billion152.575.5%n/a4.9%1.202.3%
Novartis AG NVS *$311.5 billion22.8330.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.7 billion28.5621.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$191.3 billion41.219.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$181.7 billion11.8452.8%41.3%6.4%0.674.3%
Pfizer Inc. PFE$167.3 billion41.944.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.9 billion35.2419.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$128.4 billion13.9239.5%22.6%4.2%1.834.0%
Sanofi SNY *$117.6 billion13.5710.9%n/a6.2%0.264.6%
All 174 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.35 trillion46.5168.5%n/a45.5%1.230.4%
Johnson & Johnson JNJ$675.9 billion42.5419.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$519.4 billion50.58n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$364.8 billion152.575.5%n/a4.9%1.202.3%
Novartis AG NVS *$311.5 billion22.8330.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.7 billion28.5621.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$251.6 billion26.9865.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$212.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$191.3 billion41.219.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$181.7 billion11.8452.8%41.3%6.4%0.674.3%
Pfizer Inc. PFE$167.3 billion41.944.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.9 billion35.2419.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$128.4 billion13.9239.5%22.6%4.2%1.834.0%
Sanofi SNY *$117.6 billion13.5710.9%n/a6.2%0.264.6%
GSK plc GSK *$102.8 billion13.8034.9%24.3%4.1%1.083.3%
Moderna, Inc. MRNA$101.3 billionn/a-40.8%-116.0%13.1%0.52n/a
Regeneron Pharmaceuticals, Inc. REGN$96.8 billion20.2314.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.1 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$60.1 billion49.6617.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$54.9 billion46.9563.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.5 billion98.596.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$38.7 billion45.696.9%57.1%11.4%0.881.3%
Biogen Inc. BIIB$37.4 billion108.211.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.7 billion35.1916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$33.6 billion14.0275.3%n/a1.0%2.742.5%
Roivant Sciences Ltd. ROIV$29.8 billionn/a-8.6%-1,358.1%102.1%0.00n/a
Insmed Inc. INSM$26.2 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$24.9 billion22.1919.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$23.9 billionn/a-4.4%-0.0%4.3%0.972.3%
BioNTech SE BNTX *$21.9 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.3 billion7.8775.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.3 billion21.1248.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$17.1 billion25.0918.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.8 billion83.524.9%9.0%13.5%1.33n/a
BridgeBio Pharma, Inc. BBIO$15.4 billionn/an/a-38.5%167.3%n/an/a
Kiniksa Pharmaceuticals International, plc KNSA$14.9 billion73.1415.4%13.8%58.2%0.00n/a
Elanco Animal Health Inc. ELAN$13.4 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.1511.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.7 billion26.22n/a37.4%45.0%n/an/a
Kymera Therapeutics, Inc. KYMR$11.7 billionn/a-21.6%-396.0%133.8%0.00n/a
Bio-Techne Corp. TECH$11.4 billion66.817.9%19.6%0.9%0.090.4%
Biomarin Pharmaceutical Inc. BMRN$11.1 billionn/a-0.3%3.1%18.1%0.67n/a
Madrigal Pharmaceuticals, Inc. MDGL$10.0 billionn/a-24.8%-10.7%92.8%0.54n/a
Repligen Corp. RGEN$9.9 billionn/a-0.6%2.3%13.8%0.27n/a
TG Therapeutics, Inc. TGTX$9.7 billion97.3918.5%21.5%68.8%1.30n/a
Krystal Biotech, Inc. KRYS$9.1 billion41.6015.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.9 billion28.8531.5%58.6%163.7%0.00n/a
Twist Bioscience Corp. TWST$8.3 billionn/a-30.7%-33.6%19.2%0.03n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.7619.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.9 billionn/a-220.3%-66.7%61.0%1.17n/a
Cytokinetics Inc. CYTK$7.8 billionn/an/a-625.2%29.9%n/an/a
Alkermes plc. ALKS$7.8 billionn/a-0.0%3.7%15.3%0.81n/a
Amneal Pharmaceuticals, Inc. AMRX$7.5 billion50.9325.1%15.0%8.9%5.87n/a
Axsome Therapeutics, Inc. AXSM$7.4 billionn/a-149.2%-17.5%54.2%1.78n/a
ImmunityBio, Inc. IBRX$7.2 billionn/an/a-150.2%121.2%n/an/a
Arrowhead Pharmaceuticals, Inc. ARWR$6.9 billionn/a-68.7%-33.8%16.8%1.86n/a
Lantheus Holdings, Inc. LNTH$6.6 billion25.0319.9%18.6%2.4%0.42n/a
CG Oncology, Inc. CGON$6.5 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Ligand Pharmaceuticals Inc. LGND$6.3 billion140.125.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.2 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.9 billionn/an/an/an/a1.16n/a
PTC Therapeutics, Inc. PTCT$5.4 billionn/an/a12.8%-35.1%n/an/a
Travere Therapeutics, Inc. TVTX$5.0 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.7 billionn/a-40.0%-16.2%17.9%1.90n/a
Ionis Pharmaceuticals Inc. IONS$4.7 billionn/a-138.8%-58.8%-0.7%3.36n/a
Liquidia Corp. LQDA$4.6 billionn/an/a-15.6%798.4%n/an/a
Relay Therapeutics, Inc. RLAY$4.4 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Crispr Therapeutics AG CRSP$4.4 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Tango Therapeutics, Inc. TNGX$4.1 billionn/a-21.2%n/an/a0.00n/a
AbCellera Biologics Inc. ABCL$4.1 billionn/a-14.0%-298.0%92.1%0.00n/a
Xenon Pharmaceuticals Inc. XENE$4.1 billionn/a-37.4%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Viking Therapeutics, Inc. VKTX$3.7 billionn/a-106.6%n/an/a0.43n/a
Organon & Co. OGN$3.6 billion18.2717.9%n/a-3.2%7.170.6%
Tarsus Pharmaceuticals, Inc. TARS$3.6 billionn/a-675.0%-102.0%86.3%0.700.0%
DBV Technologies S.A. DBVT$3.6 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.5 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.5 billion130.5712.3%6.9%60.0%0.45n/a
Supernus, Inc. SUPN$3.4 billion8.03n/a40.6%16.4%n/an/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.2 billion8.6626.1%10.2%14.8%0.00n/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.1 billionn/an/an/an/a0.00n/a
Vericel Corp. VCEL$3.0 billion92.278.7%8.3%25.3%0.00n/a
Xencor Inc. XNCR$2.9 billionn/a-21.0%-72.7%33.5%0.17n/a
Xeris Biopharma Holdings, Inc. XERS$2.9 billionn/a-13.3%12.7%38.4%3.89n/a
Adma Biologics, Inc. ADMA$2.8 billion16.4441.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Beam Therapeutics Inc. BEAM$2.6 billionn/a-11.2%-267.7%163.3%0.11n/a
Neogen Corp. NEOG$2.5 billionn/a-2.7%-0.8%-0.3%0.37n/a
Septerna, Inc. SEPN$2.5 billionn/a-13.8%-76.2%336.7%0.00n/a
Schrodinger, Inc. SDGR$2.4 billionn/a-19.6%-49.6%4.8%0.00n/a
Celldex Therapeutics, Inc. CLDX$2.4 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.4 billionn/a-126.5%-475.0%-58.3%0.28n/a
Perrigo Co. plc PRGO$2.3 billionn/a-72.5%-39.4%-4.5%1.356.9%
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Zymeworks Inc. ZYME$2.2 billion60.5016.8%16.6%97.8%1.31n/a
Vir Biotechnology, Inc. VIR$2.2 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1247.8%48.6%21.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.1 billion13.898.0%25.0%5.1%1.07n/a
Immunome Inc. IMNM$2.1 billionn/a-62.2%n/an/a0.00n/a
Maze Therapeutics, Inc. MAZE$2.0 billionn/an/an/an/a0.09n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Harmony Biosciences Holdings, Inc. HRMY$2.0 billion11.1116.7%22.2%19.8%0.14n/a
Eton Pharmaceuticals, Inc. ETON$1.9 billion44.3657.4%28.8%100.6%0.27n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Biocryst Pharmaceuticals Inc. BCRX$1.9 billionn/an/a-30.1%60.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.9 billionn/a-38.1%-297.7%214.4%0.00n/a
Trulieve Cannabis Corp. TRLV$1.9 billionn/a-57.8%-25.6%-9.1%0.37n/a
Generate Biomedicines, Inc. GENB$1.8 billionn/an/an/an/a0.00n/a
Stoke Therapeutics, Inc. STOK$1.8 billionn/a-69.0%-913.1%-86.3%0.00n/a
Sarepta Therapeutics, Inc. SRPT$1.8 billionn/a-7.5%-2.5%-18.9%0.56n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.8730.5%41.3%738.8%0.000.0%
Novavax Inc. NVAX$1.7 billionn/an/a-21.2%-61.3%n/an/a
Immunocore Holdings plc IMCR$1.7 billionn/a-7.7%-6.8%13.1%0.940.0%
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
Precigen, Inc. PGEN$1.6 billion129.2029.1%21.4%n/a1.12n/a
ANI Pharmaceuticals Inc. ANIP$1.6 billion14.0318.3%16.0%25.9%0.95n/a
uniQure N.V. QURE$1.6 billionn/a-79.0%-1,001.7%28.0%0.17n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Nuvation Bio Inc. NUVB$1.5 billionn/a-59.6%-61.2%654.2%1.25n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.235.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.5 billionn/a-74.1%-680.9%-9.7%0.17n/a
Phibro Animal Health Corp. PAHC$1.4 billion13.8524.6%12.5%10.1%1.761.4%
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Avalyn Pharma Inc. AVLN$1.4 billionn/an/an/an/a0.04n/a
Innoviva, Inc. INVA$1.4 billion9.5917.0%38.8%12.8%0.23n/a
Mannkind Corp. MNKD$1.4 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.3 billionn/an/an/an/an/an/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Cronos Group Inc. CRON$1.3 billion20.065.4%3.4%55.8%0.00n/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.2812.1%18.7%3.1%0.75n/a
Harrow, Inc. HROW$1.1 billionn/a-97.6%-2.0%21.3%10.03n/a
Cryoport, Inc. CYRX$1.1 billionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$957 millionn/an/an/an/a0.00n/a
Aktis Oncology, Inc. AKTS$934 millionn/an/an/an/a0.00n/a
MeiraGTx Holdings plc MGTX$906 million13.5436.6%46.3%948.3%0.46n/a
Monte Rosa Therapeutics, Inc. GLUE$896 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$851 millionn/an/a-61.7%159.5%n/an/a
Lexicon Pharmaceuticals, Inc. LXRX$838 millionn/a-38.1%-147.4%-45.6%0.32n/a
Rigel Pharmaceuticals Inc. RIGL$827 million2.8369.0%26.3%2.2%0.02n/a
Verastem, Inc. VSTM$824 millionn/an/an/an/a11.82n/a
Ironwood Pharmaceuticals Inc. IRWD$797 million5.35n/a62.9%18.1%n/an/a
QuidelOrtho Corp. QDEL$791 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ginkgo Bioworks Holdings, Inc. DNA$775 millionn/a-63.9%-242.5%-44.2%0.00n/a
Nektar Therapeutics NKTR$770 millionn/a-17.4%-257.8%-27.2%0.00n/a
Arbutus Biopharma Corp. ABUS$762 million3.38256.5%81.1%1,142.6%0.00n/a
Collegium Pharmaceutical, Inc. COLL$760 million24.4612.9%15.2%7.7%3.65n/a
Ardelyx, Inc. ARDX$754 millionn/a-33.8%-7.7%17.6%1.54n/a
Janux Therapeutics, Inc. JANX$736 millionn/a-11.0%-599.3%132.9%0.00n/a
Zevra Therapeutics, Inc. ZVRA$709 million9.8632.7%60.8%75.1%0.00n/a
Kura Oncology, Inc. KURA$695 millionn/a-1,630.7%-394.3%n/a0.55n/a
Design Therapeutics, Inc. DSGN$679 millionn/a-36.6%n/an/a0.00n/a
Wave Life Sciences, Inc. WVE$671 millionn/a-52.4%-320.9%n/a0.00n/a
Geron Corp. GERN$627 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$626 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$541 millionn/a-48.0%-14.3%-2.6%0.45n/a
Monopar Therapeutics MNPR$481 millionn/an/an/an/a0.00n/a
Arvinas, Inc. ARVN$452 millionn/a-1.8%-12.1%-11.8%0.00n/a
Gyre Therapeutics, Inc. GYRE$452 millionn/a-37.5%-20.6%13.5%0.00n/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$442 millionn/an/a-9.3%86.8%n/an/a
Aquestive Therapeutics, Inc. AQST$442 millionn/an/a-114.1%12.5%n/an/a
CytomX Therapeutics, Inc. CTMX$434 millionn/a-30.0%-676.5%-87.7%0.00n/a
Puma Biotechnology, Inc. PBYI$420 million17.6516.3%11.3%9.4%0.00n/a
CorMedix Inc. CRMD$416 million2.5040.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$386 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$251 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$141 millionn/an/an/an/an/an/a
Gossamer Bio, Inc. GOSS$69 millionn/an/a-140.0%78.0%n/an/a
124 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

Annual reports on EDGAR

FormYear toFiled
20-F31 March 202629 May 2026EDGAR
20-F31 March 20256 June 2025EDGAR
20-F31 March 202412 June 2024EDGAR
20-F31 March 202313 June 2023EDGAR
20-F31 March 202227 June 2022EDGAR
20-F31 March 202130 June 2021EDGAR
20-F31 March 202015 June 2020EDGAR
20-F31 March 20193 June 2019EDGAR
20-F/A31 March 201812 July 2018EDGAR
20-F31 March 201815 June 2018EDGAR
20-F31 March 201719 June 2017EDGAR